We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

92 hedge funds and large institutions have $255M invested in Dianthus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 25

17% more capital invested

Capital invested by funds: $217M → $255M (+$37.9M)

0.07% more ownership

Funds ownership: 4.14% → 4.21% (+0.07%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2% less funds holding

Funds holding: 94 → 92 (-2)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

72% less call options, than puts

Call options by funds: $46K | Put options by funds: $164K

Holders
92
Holders Change
-2
Holders Change %
-2.13%
% of All Funds
1.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
7
Increased
35
Reduced
25
Closed
8
Calls
$46K
Puts
$164K
Net Calls
-$118K
Net Calls Change
-$32K

Top Buyers

1
ACM
Aquilo Capital Management
California
+$9.27M
2
JP Morgan Chase
JP Morgan Chase
New York
+$1.51M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.13M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$960K
5
PIM
Platinum Investment Management
Australia
+$834K

Top Sellers

1
EAM
Eventide Asset Management
Massachusetts
-$9.63M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.05M
3
PM
Prosight Management
Texas
-$840K
4
Squarepoint
Squarepoint
New York
-$376K
5
UBS AM
UBS AM
Illinois
-$368K
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP IV
Massachusetts
$62.8M – – –
GGHC
2
Gilder Gagnon Howe & Co
New York
$33.1M -$334K -2,942 -1%
CC
3
Casdin Capital
New York
$26.2M – – –
AI
4
Alphabet Inc
California
$26.2M – – –
ACM
5
Aquilo Capital Management
California
$17.8M +$9.27M +81,737 +136%
BlackRock
6
BlackRock
New York
$14.1M +$241K +2,128 +2%
Vanguard Group
7
Vanguard Group
Pennsylvania
$10.4M +$960K +8,467 +11%
EAM
8
Eventide Asset Management
Massachusetts
$7.84M -$9.63M -84,978 -58%
UBS AM
9
UBS AM
Illinois
$4.37M -$368K -3,244 -9%
BL
10
Bleichroeder LP
New York
$3.41M +$585K +5,158 +23%
PAI
11
Palo Alto Investors
California
$3.35M +$591K +5,213 +24%
Morgan Stanley
12
Morgan Stanley
New York
$2.88M +$638K +5,628 +33%
State Street
13
State Street
Massachusetts
$2.83M +$41.8K +369 +2%
PIM
14
Platinum Investment Management
Australia
$2.82M +$834K +7,355 +49%
HMC
15
Harvard Management Company
Massachusetts
$2.61M – – –
JP Morgan Chase
16
JP Morgan Chase
New York
$2.38M +$1.51M +13,283 +232%
Northern Trust
17
Northern Trust
Illinois
$2.3M -$1.81K -16 -0.1%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.26M -$3.85K -34 -0.2%
Principal Financial Group
19
Principal Financial Group
Iowa
$1.99M +$104K +913 +6%
Bessemer Group
20
Bessemer Group
New Jersey
$1.86M – – –
Renaissance Technologies
21
Renaissance Technologies
New York
$1.68M -$1.05M -9,281 -41%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$1.67M +$186K +1,637 +14%
Two Sigma Investments
23
Two Sigma Investments
New York
$1.56M +$80.2K +707 +6%
Jacobs Levy Equity Management
24
Jacobs Levy Equity Management
New Jersey
$1.53M +$1.13M +9,934 +436%
TCM
25
Tekla Capital Management
Massachusetts
$1.51M – – –
1
2 3 4

DNTH Hedge Fund Activity: Q4 2020 in Review

92 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2020, worth a combined $255M — up 17% from $217M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of DNTH and 7 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 35 added.

The largest buyer was Aquilo Capital Management, adding an estimated $9.27M. The largest seller was Eventide Asset Management, cutting an estimated $9.63M.

  • 92 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2020, down from 94 in Q3 2020.
  • Funds reported $255M of Dianthus Therapeutics stock for Q4 2020, up 17% quarter-over-quarter.
  • 7 funds opened new Dianthus Therapeutics positions in Q4 2020 and 8 closed out, a net change of -1 holder.
  • The largest Dianthus Therapeutics buyer in Q4 2020 was Aquilo Capital Management, an estimated $9.27M added.
  • The largest Dianthus Therapeutics seller in Q4 2020 was Eventide Asset Management, an estimated $9.63M sold.

Based on aggregated 13F filings for Q4 2020.